In Kundl, medicines containing penicillin are manufactured, from the active ingredient to the finished, packaged tablet. This only happens at this location across Europe. The increase in production volumes achieved with the current factory expansion is a strong commitment by the company to Austria. At the same time, this can also make a contribution to improving the supply situation for antibiotics.
Mag. Alexander Herzog, Secretary General of PHARMIG
Vienna (OTS) – The PHARMIG member company Sandoz has expanded its antibiotic production in Kundl and can thus make a significant contribution to increasing security of supply.
On the occasion of today’s opening of the factory expansion at the Sandoz site in Kundl, Tyrol, PHARMIG Secretary General Alexander Herzog is pleased about the resulting increase in antibiotic production in Austria: “In Kundl, medicines containing penicillin are manufactured, from the active ingredient to the fully packaged tablet. This only happens at this location across Europe. The increase in production volumes achieved with the current factory expansion is a strong commitment by the company to Austria. At the same time, this can also make a contribution to improving the supply situation for antibiotics.”
With this latest investment of 50 million euros, Sandoz is increasing its production capacity from the current 200 to 240 million packs per year. Apart from this, investments are also being made in automation technology and innovative technologies, which means that the amount of antibiotic dry juices used in medicines for children can also be doubled.
“Pharmaceutical companies prove again and again with their investments that they are sticking to Austria and therefore Europe as a location. “But ultimately there are still isolated success stories that should not hide the fact that the general conditions for pharmaceutical companies are becoming increasingly difficult, especially when it comes to local pricing and reimbursement policies,” said Herzog.
In order to make Austria competitive as a location for drug production and development in the European and international context in the long term, a long-term strategy is essential. This requires that industry, business, health, science and politics act together in the spirit of an integrated location policy. Herzog says: “I am convinced that competitiveness, a lively research and development landscape and predictable economic conditions do not have to contradict each other in health care. This applies to both Europe and Austria.”
About PHARMIG: PHARMIG is the voluntary interest group of the Austrian pharmaceutical industry. The association currently has around 120 members (as of March 2024), who cover a good 95 percent of the medication market. PHARMIG and its member companies stand for the best possible security of supply of medicines in the healthcare system and ensure social and medical progress through quality and innovation.
Questions & Contact:
PHARMIG – Association of the Austrian Pharmaceutical Industry
Peter Richter, BA MA MBA
Head of Communications & PR
+43 664 8860 5264
peter.richter@pharmig.at
www.pharmig.at